Become a donor—save lives

Every day, 20 people die while waiting for an organ transplant. Just one donor can save and heal up to 75 lives through organ and tissue donation. Today, there are more than 114,000 patients waiting for a lifesaving organ transplant and many more who need cornea, tissue, bone marrow, blood, and platelet donations. There are 2 ways to become a donor:

  1. Deceased organ donors—can donate both kidneys, liver, both lungs, heart, pancreas, and intestines.
  2. Living organ donor—can donate one kidney, one lung, or a portion of the liver, pancreas, or intestines.

Inflammation in middle age may indicate increased risk of dementia in later life

The latest findings from the Atherosclerosis Risk in Communities (ARIC) Study indicate that people suffering chronic inflammation during middle age show a greater decline in cognitive function as they get older.

Brain with inflammationSklemine Kirill | Shutterstock

When the body sustains an injury, it raises an acute inflammatory response to fight off infection and promote healing. This inflammatory response is localized and short-lived, and forms part of a healthy immune system.

Study identifies protein regulator that induces Th17 cells to cause multiple sclerosis

Inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, and multiple sclerosis (MS) are a major healthcare burden worldwide and are life-altering conditions for afflicted patients. Yet, while much is known about the mechanisms of disease, in most cases there are very few effective treatment options.

However, a recent study published in Nature Communications provides hope for autoimmune disease sufferers. Led by researchers from Osaka University, the study team found that genome organizer protein Satb1 triggers a shift in immune cells, inducing tissue inflammation and autoimmunity. This breakthrough could lead to new treatments targeting the source of inflammation.

Texans Can Appeal Surprise Medical Bills, But The Process Can Be Draining

In Texas, a growing number of patients are turning to a little-known state mediation program to deal with unexpected hospital bills.

The bills in question often arrive in patients’ mailboxes with shocking balances that run into the tens or even hundreds of thousands of dollars.

When patients, through no fault of their own, are treated outside their insurers’ network of hospitals, the result can be a surprise bill. Other times, insurers won’t agree to pay what the hospital charges, and the patient is on the hook for the balance.

Heart attack tied to edible marijuana is a warning to doctors

(Reuters Health) – As medical and recreational marijuana becomes legal in more and more places, experts worry there isn’t enough science on the risks and benefits of the drug, especially for patients with heart disease.

In a new case report, doctors describe the heart attack of a man who ate a lollipop laced with high levels of TCH, marijuana’s psychoactive ingredient. This patient’s story may serve as a warning that cannabis isn’t as benign as some would like to think, doctors write in the Canadian Journal of Cardiology.

Clinigen agrees to buy U.S. rights to Novartis’ cancer drug Proleukin

(Reuters) – British pharmaceutical firm Clinigen Group Plc said on Wednesday it had agreed to acquire the U.S. rights to Swiss drugmaker Novartis AG’s skin and lung cancer drug Proleukin for a total of $210 million, including some future payments.

The deal will give Clinigen global rights to the drug and the company expects the deal to add to its profitability this year, and forecast a growth in adjusted EBITDA for the six months ended December.

(This story corrects headline and paragraphs 1 and 2 to clarify that deal has been agreed but not yet completed)

FDA Warns 17 Companies About Illegal Alzheimer’s Disease Products

A number of warning/advisory letters have been issued to 17 companies for selling illegal products that claim to prevent, treat or cure Alzheimer’s disease and other serious conditions, the U.S. Food and Drug Administration says.

Latest Alzheimer’s News

The agency said it posted 12 warning letters and five online advisory letters to U.S. and foreign companies illegally selling more than 58 products, many of which are marketed as dietary supplements.

The products — which include tablets, capsules and oils and are often sold on websites and social media — have not been reviewed by the FDA and may be ineffective, unsafe and could prevent a person from seeking an appropriate diagnosis and treatment, according to the FDA

Researchers examine link between OSA and inflammation, organ damage

Understanding mechanisms of apnea-related inflammation could lead to more precise treatments, improved outcomes for total health

Voyagers no longer embark in search of the storied Fountain of Youth, but the quest for longevity is still very much alive for researchers.

“Aging has become the next frontier in medicine,” said renowned sleep specialist David Gozal, MD, chair of the Department of Child Health at the University of Missouri School of Medicine.

False Lead: Senator’s Offer To Help Patient Import Cheap Insulin Goes Nowhere

It sounded like an answer to prayers for millions with diabetes struggling to pay soaring prices for insulin.

At a congressional hearing last month, Sen. Mike Enzi said an adviser had found “a foundation to import insulin for a number of people at lower cost.” The Wyoming Republican told the mother of a young man with Type 1 diabetes that his adviser “worked through a foundation so that it would be legal, and I will share that with you.”

U.S. FDA panel recommends approval of Johnson & Johnson’s depression drug

FILE PHOTO: A Johnson & Johnson building is shown in Irvine, California, U.S., January 24, 2017. REUTERS/Mike Blake

(Reuters) – An advisory panel to the U.S. Food and Drug Administration on Tuesday recommended Johnson & Johnson’s experimental nasal spray, which has a compound similar to often-abused ketamine, for patients suffering from depression.

The panel voted 14-2 in favor of the drug esketamine, developed to treat major depression in patients who have not benefited from at least two different therapies, saying its benefits outweighed the risks.

One member in the panel abstained from voting on the question.